Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft

References

• AlettiGDPodratzKCClibyWAGostoutBSStage IV ovarian cancer: disease site-specific rationale for postoperative treatmentGynecol Oncol20091121222718947860
   PubMed Web of Science ®Google Scholar
• BarnesMNGrizzleWEGrubbsCJPartridgeEEParadigms for primary prevention of ovarian carcinomaCA Cancer J Clin200252421622512139233
   PubMed Web of Science ®Google Scholar
• AuJLJangSHWientjesMGClinical aspects of drug delivery to tumorsJ Control Release2002781–3819511772451
   PubMed Web of Science ®Google Scholar
• LuZWangJWientjesMGAuJLIntraperitoneal therapy for peritoneal cancerFuture Oncol20106101625164121062160
   PubMed Web of Science ®Google Scholar
• Echarri GonzalezMJGreenRMuggiaFMIntraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when?Oncology (Williston Park)201125215616517021456387
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYHanniganEVIntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancerN Engl J Med199633526195019558960474
   PubMed Web of Science ®Google Scholar
• MarkmanMBundyBNAlbertsDSPhase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJ Clin Oncol20011941001100711181662
   PubMed Web of Science ®Google Scholar
• WenzelLBHuangHQArmstrongDKWalkerJLCellaDGynecologic Oncology GroupHealth-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200725443744317264340
   PubMed Web of Science ®Google Scholar
• ElferinkFvan der VijghWJKleinIten Bokkel HuininkWWDubbelmanRMcVieJGPharmacokinetics of carboplatin after intraperitoneal administrationCancer Chemother Pharmacol198821157603277734
   PubMed Web of Science ®Google Scholar
• ZimmSClearySMLucasWEPhase I/pharmacokinetic study of intraperitoneal cisplatin and etoposideCancer Res1987476171217163815369
   PubMed Web of Science ®Google Scholar
• MiyagiYFujiwaraKKigawaJIntraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy: a comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin; a Sankai Gynecology Study Group (SGSG) studyGynecol Oncol200599359159616095677
   PubMed Web of Science ®Google Scholar
• FujiwaraKMarkmanMMorganMColemanRLIntraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancerGynecol Oncol2005971101515790431
   PubMed Web of Science ®Google Scholar
• FujiwaraKSakuragiNSuzukiSFirst-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-upGynecol Oncol200390363764313678738
   PubMed Web of Science ®Google Scholar
• FujiwaraKAotaniEHamanoTA randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancerJpn J Clin Oncol201141227828220937602
   PubMed Web of Science ®Google Scholar
• FujiwaraKNagaoSKigawaJPhase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group studyInt J Gynecol Cancer200919583483719574769
   PubMed Web of Science ®Google Scholar
• KelemenLEThe role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?Int J Cancer2006119224325016453285
   PubMed Web of Science ®Google Scholar
• SpannuthWASoodAKColemanRLFarletuzumab in epithelial ovarian carcinomaExpert Opin Biol Ther201010343143720092424
   PubMed Web of Science ®Google Scholar
• KonnerJABell-McGuinnKMSabbatiniPFarletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I studyClin Cancer Res201016215288529520855460
   PubMed Web of Science ®Google Scholar
• WooJChiuGNKarlssonGUse of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomesInt J Pharm20083491–2384617728083
   PubMed Web of Science ®Google Scholar
• FiskeCHSubbarowYThe colorimetric determination of phosphorusJ Biol Chem1925662375400
   Google Scholar
• TurkMJWatersDJLowPSFolate-conjugated liposomes preferentially target macrophages associated with ovarian carcinomaCancer Lett2004213216517215327831
   PubMed Web of Science ®Google Scholar
• BandakSGorenDHorowitzATzemachDGabizonAPharmacological studies of cisplatin encapsulated in long- circulating liposomes in mouse tumor modelsAnticancer Drugs1999101091192010630359
   PubMed Web of Science ®Google Scholar
• PanXQWangHLeeRJAntitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft modelPharm Res200320341742212669962
   PubMed Web of Science ®Google Scholar
• GadducciACarninoFChiaraSIntraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-OvestGynecol Oncol200076215716210637064
   PubMed Web of Science ®Google Scholar
• LowPSAntonyACFolate receptor-targeted drugs for cancer and inflammatory diseasesAdv Drug Deliv Rev20045681055105815094205
   PubMed Web of Science ®Google Scholar
• GabizonAShmeedaHHorowitzATZalipskySTumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid- PEG conjugatesAdv Drug Deliv Rev20045681177119215094214
   PubMed Web of Science ®Google Scholar
• PratesiGTortoretoMCortiCGiardiniRZuninoFSuccessful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenograftsBr J Cancer19957135255287880734
   PubMed Web of Science ®Google Scholar
• FichtnerIReszkaRGoanSRNaundorfHCarboplatin-liposomes (CPL) in immunodeficient mice: improved antitumor activity for breast carcinomas and stimulation of hematopoiesisMed Oncol1994113–41111197633830
   PubMed Web of Science ®Google Scholar
• JandialDDMesserKFarshchi-HeydariSPuMHowellSBTumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer modelGynecol Oncol2009115336236619775736
   PubMed Web of Science ®Google Scholar